A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders

U. Basile, F. Gulli, M. A. Isgrò, C. Napodano, K. Pocino, S. A. Santini, L. Gragnani, L. Conti, E. Rossi, I. Cordone, A. L. Zignego, G. L. Rapaccini, G. Cigliana, F. Berruti, L. Todi, M. Marino, E. Di Stasio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: Monoclonal plasma cell proliferative disorders comprise a wide spectrum of diseases associated to clonal B-cell expansion. Serum protein electrophoretic profile (SPEP) and circulating free light chains (FLCs) levels are the mainstay of diseases management. Recently, soluble (s) Syndecan-1 (SDC1, CD138) produced by myeloma plasma cells has been suggested in the monitoring and follow-up of patients with myeloma. The aim of our study is to evaluate sCD138 in addition with FLCs and SPEP for the screening of patients with different evolutive disease pathways. PATIENTS AND METHODS: Sera from 73 patients with monoclonal gammopathy of undetermined significance (MGUS), 120 smoldering and 42 multiple myeloma (SMM and MM, respectively), 70 HCV-related mixed cryoglobulinemia (MC), 35 B-cell non-Hodgkin's lymphoma (B-NHL) and sera from 50 healthy donors (HD), were tested for sCD138, FLCs (assessed by means of ELISA and turbidimetric assay, respectively) and electrophoresis pattern (performed on Capillarys system) for the generation of a novel biomarker score (BS). RESULTS: Our results were grouped according to the two main lines of disease progression (vs. MM or B-NHL): In one group we found BS mean values of 0.2, 3.4, 5.3, 7.1 for HD, MGUS, SMM and MM, respectively; in the other group of 0.2, 4.4, 6.7 for HD, MC and B-NHL. CONCLUSIONS: We showed that BS mean values follow the ingravescence disease status towards the two main lines of progression to cancerous conditions; it could represent an additional useful tool in the management of screening and/or follow-up.

Original languageEnglish
Pages (from-to)4293-4302
Number of pages10
JournalEuropean Review for Medical and Pharmacological Sciences
Volume23
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • B-cell non-Hodgkin's lymphoma
  • Biomarker
  • Free Light Chains
  • HCV
  • Mixed Cryoglobulinemia
  • Monoclonal Gammopathy
  • Multiple myeloma
  • sCD138

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders. / Basile, U.; Gulli, F.; Isgrò, M. A.; Napodano, C.; Pocino, K.; Santini, S. A.; Gragnani, L.; Conti, L.; Rossi, E.; Cordone, I.; Zignego, A. L.; Rapaccini, G. L.; Cigliana, G.; Berruti, F.; Todi, L.; Marino, M.; Di Stasio, E.

In: European Review for Medical and Pharmacological Sciences, Vol. 23, No. 10, 01.01.2019, p. 4293-4302.

Research output: Contribution to journalArticle

@article{a312b1ae33134985944ab30f65e48205,
title = "A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders",
abstract = "OBJECTIVE: Monoclonal plasma cell proliferative disorders comprise a wide spectrum of diseases associated to clonal B-cell expansion. Serum protein electrophoretic profile (SPEP) and circulating free light chains (FLCs) levels are the mainstay of diseases management. Recently, soluble (s) Syndecan-1 (SDC1, CD138) produced by myeloma plasma cells has been suggested in the monitoring and follow-up of patients with myeloma. The aim of our study is to evaluate sCD138 in addition with FLCs and SPEP for the screening of patients with different evolutive disease pathways. PATIENTS AND METHODS: Sera from 73 patients with monoclonal gammopathy of undetermined significance (MGUS), 120 smoldering and 42 multiple myeloma (SMM and MM, respectively), 70 HCV-related mixed cryoglobulinemia (MC), 35 B-cell non-Hodgkin's lymphoma (B-NHL) and sera from 50 healthy donors (HD), were tested for sCD138, FLCs (assessed by means of ELISA and turbidimetric assay, respectively) and electrophoresis pattern (performed on Capillarys system) for the generation of a novel biomarker score (BS). RESULTS: Our results were grouped according to the two main lines of disease progression (vs. MM or B-NHL): In one group we found BS mean values of 0.2, 3.4, 5.3, 7.1 for HD, MGUS, SMM and MM, respectively; in the other group of 0.2, 4.4, 6.7 for HD, MC and B-NHL. CONCLUSIONS: We showed that BS mean values follow the ingravescence disease status towards the two main lines of progression to cancerous conditions; it could represent an additional useful tool in the management of screening and/or follow-up.",
keywords = "B-cell non-Hodgkin's lymphoma, Biomarker, Free Light Chains, HCV, Mixed Cryoglobulinemia, Monoclonal Gammopathy, Multiple myeloma, sCD138",
author = "U. Basile and F. Gulli and Isgr{\`o}, {M. A.} and C. Napodano and K. Pocino and Santini, {S. A.} and L. Gragnani and L. Conti and E. Rossi and I. Cordone and Zignego, {A. L.} and Rapaccini, {G. L.} and G. Cigliana and F. Berruti and L. Todi and M. Marino and {Di Stasio}, E.",
year = "2019",
month = "1",
day = "1",
doi = "10.26355/eurrev_201905_17934",
language = "English",
volume = "23",
pages = "4293--4302",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "10",

}

TY - JOUR

T1 - A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders

AU - Basile, U.

AU - Gulli, F.

AU - Isgrò, M. A.

AU - Napodano, C.

AU - Pocino, K.

AU - Santini, S. A.

AU - Gragnani, L.

AU - Conti, L.

AU - Rossi, E.

AU - Cordone, I.

AU - Zignego, A. L.

AU - Rapaccini, G. L.

AU - Cigliana, G.

AU - Berruti, F.

AU - Todi, L.

AU - Marino, M.

AU - Di Stasio, E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - OBJECTIVE: Monoclonal plasma cell proliferative disorders comprise a wide spectrum of diseases associated to clonal B-cell expansion. Serum protein electrophoretic profile (SPEP) and circulating free light chains (FLCs) levels are the mainstay of diseases management. Recently, soluble (s) Syndecan-1 (SDC1, CD138) produced by myeloma plasma cells has been suggested in the monitoring and follow-up of patients with myeloma. The aim of our study is to evaluate sCD138 in addition with FLCs and SPEP for the screening of patients with different evolutive disease pathways. PATIENTS AND METHODS: Sera from 73 patients with monoclonal gammopathy of undetermined significance (MGUS), 120 smoldering and 42 multiple myeloma (SMM and MM, respectively), 70 HCV-related mixed cryoglobulinemia (MC), 35 B-cell non-Hodgkin's lymphoma (B-NHL) and sera from 50 healthy donors (HD), were tested for sCD138, FLCs (assessed by means of ELISA and turbidimetric assay, respectively) and electrophoresis pattern (performed on Capillarys system) for the generation of a novel biomarker score (BS). RESULTS: Our results were grouped according to the two main lines of disease progression (vs. MM or B-NHL): In one group we found BS mean values of 0.2, 3.4, 5.3, 7.1 for HD, MGUS, SMM and MM, respectively; in the other group of 0.2, 4.4, 6.7 for HD, MC and B-NHL. CONCLUSIONS: We showed that BS mean values follow the ingravescence disease status towards the two main lines of progression to cancerous conditions; it could represent an additional useful tool in the management of screening and/or follow-up.

AB - OBJECTIVE: Monoclonal plasma cell proliferative disorders comprise a wide spectrum of diseases associated to clonal B-cell expansion. Serum protein electrophoretic profile (SPEP) and circulating free light chains (FLCs) levels are the mainstay of diseases management. Recently, soluble (s) Syndecan-1 (SDC1, CD138) produced by myeloma plasma cells has been suggested in the monitoring and follow-up of patients with myeloma. The aim of our study is to evaluate sCD138 in addition with FLCs and SPEP for the screening of patients with different evolutive disease pathways. PATIENTS AND METHODS: Sera from 73 patients with monoclonal gammopathy of undetermined significance (MGUS), 120 smoldering and 42 multiple myeloma (SMM and MM, respectively), 70 HCV-related mixed cryoglobulinemia (MC), 35 B-cell non-Hodgkin's lymphoma (B-NHL) and sera from 50 healthy donors (HD), were tested for sCD138, FLCs (assessed by means of ELISA and turbidimetric assay, respectively) and electrophoresis pattern (performed on Capillarys system) for the generation of a novel biomarker score (BS). RESULTS: Our results were grouped according to the two main lines of disease progression (vs. MM or B-NHL): In one group we found BS mean values of 0.2, 3.4, 5.3, 7.1 for HD, MGUS, SMM and MM, respectively; in the other group of 0.2, 4.4, 6.7 for HD, MC and B-NHL. CONCLUSIONS: We showed that BS mean values follow the ingravescence disease status towards the two main lines of progression to cancerous conditions; it could represent an additional useful tool in the management of screening and/or follow-up.

KW - B-cell non-Hodgkin's lymphoma

KW - Biomarker

KW - Free Light Chains

KW - HCV

KW - Mixed Cryoglobulinemia

KW - Monoclonal Gammopathy

KW - Multiple myeloma

KW - sCD138

UR - http://www.scopus.com/inward/record.url?scp=85067443981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067443981&partnerID=8YFLogxK

U2 - 10.26355/eurrev_201905_17934

DO - 10.26355/eurrev_201905_17934

M3 - Article

C2 - 31173301

AN - SCOPUS:85067443981

VL - 23

SP - 4293

EP - 4302

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 10

ER -